Dasatinib treatment at 10 μM inhibits the phosphorylation of Src, EGFR, STAT‐3, STAT‐5, PKB and ERK‐1/2 in YD‐38 human oral cancer cells. This evidence concerns the gene MAPK3 and lip and oral cavity carcinoma.